托珠单抗治疗原发性干燥综合征的多中心双盲随机安慰剂对照试验
这项多中心双盲随机安慰剂对照试验纳入110例符合AECG标准且ESSDAI≥5的原发性干燥综合征患者,比较每4周静脉输注托珠单抗与安慰剂共6次的疗效。第24周达到主要终点者在托珠单抗组为52.7%,在安慰剂组为63.6%,差异为-11.4%(95%可信区间-30.6至9.0),未显示获益。
要点
- 在原发性干燥综合征伴系统并发症患者中,托珠单抗未优于安慰剂。
- 第24周主要终点应答率为52.7% vs 63.6%,差异-11.4%。
- 研究未达到主要疗效终点,不支持IL-6受体抑制用于该人群。
核心结论
- 在原发性干燥综合征患者中,托珠单抗治疗24周未较安慰剂改善系统受累与症状。
研究设计与样本
- 多中心双盲随机安慰剂对照试验,2013年7月24日至2018年7月16日,随访44周,涉及17家转诊中心。
- 纳入符合美国欧洲共识组(AECG)标准且ESSDAI≥5的原发性干燥综合征患者,随机接受6次每月输注托珠单抗或安慰剂。
- 共110例患者,托珠单抗组55例(平均年龄50.9岁,女性98.2%),安慰剂组55例(平均年龄54.8岁,女性90.9%)。
主要发现
- 第24周达到主要终点者托珠单抗组为52.7%(29/55),安慰剂组为63.6%(35/55)。
- 两组应答率差异为-11.4%(95%可信区间-30.6至9.0),Pr[Toc>Pla]=0.14。
关键数值与推荐
- 主要终点为第24周应答,定义为ESSDAI下降至少3分、ESSDAI任何新领域未出现中重度活动、医师总体评估(视觉数字量表)未较入组恶化≥1/10。
- ESSDAI入选阈值为≥5分。
临床怎么用
- 对原发性干燥综合征相关系统并发症,不应以托珠单抗作为改善系统受累的治疗选择。
局限性
- 原文摘要未报告局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: No immunomodulatory drug has been approved for primary Sjögren's syndrome, a systemic autoimmune disease affecting 0.1% of the population. To demonstrate the efficacy of targeting interleukin 6 receptor in patients with Sjögren's syndrome-related systemic complications. METHODS: Multicentre double-blind randomised placebo-controlled trial between 24 July 2013 and 16 July 2018, with a follow-up of 44 weeks, involving 17 referral centres. Inclusion criteria were primary Sjögren's syndrome according to American European Consensus Group criteria and score ≥5 for the EULAR Sjögren's Syndrome Disease activity Index (ESSDAI, score of systemic complications). Patients were randomised to receive either 6 monthly infusions of tocilizumab or placebo. The primary endpoint was response to treatment at week 24. Response to treatment was defined by the combination of (1) a decrease of at least 3 points in the ESSDAI, (2) no occurrence of moderate or severe activity in any new domain of the ESSDAI and (3) lack of worsening in physician's global assessment on a Visual Numeric Scale ≥1/10, all as compared with enrolment. RESULTS: 110 patients were randomised, 55 patients to tocilizumab (mean (SD) age: 50.9 (12.4) years; women: 98.2%) and 55 patients to placebo (54.8 (10.7) years; 90.9%). At 24 weeks, the proportion of patients meeting the primary endpoint was 52.7% (29/55) in the tocilizumab group and 63.6% (35/55) in the placebo group, for a difference of -11.4% (95% credible interval -30.6 to 9.0) (Pr[Toc >Pla]=0.14). CONCLUSION: Among patients with primary Sjögren's syndrome, the use of tocilizumab did not improve systemic involvement and symptoms over 24 weeks of treatment compared with placebo. TRIAL REGISTRATION NUMBER: NCT01782235.
引用
- Felten R, Devauchelle-Pensec V, Seror R, et al. Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial. Ann Rheum Dis. 2020. PMID: 33208345. doi:10.1136/annrheumdis-2020-218467
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。